Literature DB >> 10207538

Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue.

L Ruiz1, J van Lunzen, A Arno, H J Stellbrink, C Schneider, M Rull, E Castellà, I Ojanguren, D D Richman, B Clotet, K Tenner-Racz, P Racz.   

Abstract

OBJECTIVE: Lymphoid tissue provides a reservoir where HIV can persist. However, therapies incorporating a protease inhibitor can target this reservoir. This study was designed to investigate the relative long-term effects on lymph-node viral load and cellular architecture of regimens containing multiple nucleosides alone or in combination with protease inhibitors.
METHODS: Axillary lymph-node biopsies from 12 patients with undetectable viraemia (viral load < 20 copies/ml: mean CD4 cells 525 x 10(6)/l) for a mean period of 25 months (range, 10-52 months) were investigated for the presence of HIV by in situ hybridization and coculture. Four patients were receiving multiple nucleoside analogues alone or in one case with a suboptimally dosed protease inhibitor (group I). Protease inhibitor was added to the regimen of seven patients at least 6 months prior to lymph-node biopsy (group II). Standard flow cytometry and virological data were obtained from peripheral blood every 3 months.
RESULTS: By in situ hybridization, more productively infected CD4+ T cells were found in the lymph nodes of group I patients treated with nucleoside analogues alone. Very low numbers of productively infected lymph node cells were detected in the protease inhibitor-treated group II. No trapping of virions on the follicular dendritic cell (FDC) network was detectable in protease inhibitor-treated patients. In contrast, large deposits of FDC-bound virions were observed in three out of five patients from group I. Virus cultures from lymph node cells were positive in these three group I patients compared with only one out of seven patients from group II. Sequencing reverse transcriptase and protease genes from these isolates revealed typical mutations conferring resistance to the previously administered nucleoside analogue. A more preserved lymph node architecture and less signs of immunopathological change were also observed in protease inhibitor-treated patients.
CONCLUSIONS: Undetectable plasma viraemia using the ultrasensitive PCR assay for prolonged periods of time does not always reflect complete HIV-1 suppression within the lymphoid compartment. Our results suggest that protease inhibitor-containing regimens target HIV reservoirs in lymphoid tissue more effectively and preserve or restore lymph node architecture.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207538     DOI: 10.1097/00002030-199901140-00001

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

Review 1.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

Review 2.  HIV persistence: chemokines and their signalling pathways.

Authors:  Vanessa A Evans; Gabriela Khoury; Suha Saleh; Paul U Cameron; Sharon R Lewin
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-28       Impact factor: 7.638

3.  Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection.

Authors:  H Kuster; M Opravil; P Ott; E Schlaepfer; M Fischer; H F Günthard; R Lüthy; R Weber; R W Cone
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 4.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

5.  Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells.

Authors:  Aaron N Endsley; Rodney J Y Ho
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

6.  Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion.

Authors:  Olivier Bourry; Abdelkrim Mannioui; Pierre Sellier; Camille Roucairol; Lucie Durand-Gasselin; Nathalie Dereuddre-Bosquet; Henri Benech; Pierre Roques; Roger Le Grand
Journal:  Retrovirology       Date:  2010-09-26       Impact factor: 4.602

Review 7.  Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Authors:  D P Figgitt; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

8.  Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l.

Authors:  J J Lum; A A Pilon; J Sanchez-Dardon; B N Phenix; J E Kim; J Mihowich; K Jamison; N Hawley-Foss; D H Lynch; A D Badley
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles.

Authors:  Aaron N Endsley; Rodney J Y Ho
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

Review 10.  NanoART, neuroAIDS and CNS drug delivery.

Authors:  Ari Nowacek; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.